Consistently, when 4T1 tumor-bearing mice with myeloid TβRII deficiency (TβRIIMyeKO) or wildtype were treated with NT157, an inhibitor of IGF1R signaling, there was a synergistic anti-metastasis effect compared with that from TβRIIMyeKO or NT157 treatment alone (Fig. 5g). The gene discussed is IGF1R; the disease is neoplasm.